Treg Cell Therapy for Inducing Transplantation Tolerance | Qizhi Tang

Qizhi Tang received her PhD in immunology from the University of Illinois at Chicago. She completed postdoctoral fellowships investigating mechanisms of immune tolerance at the University of Chicago and UCSF. She joined the faculty at UCSF in 2002 as an assistant professor of pathology in the Diabetes Center where she researched mechanisms of immune tolerance. She joined the transplantation division in the department of surgery in 2007 to lead basic research and translational research in transplant immunology. She has been the director of the UCSF Transplantation Research Laboratory since 2007. A major research focus in the Tang Lab is on regulatory T cell therapy for autoimmune diseases and transplantation, and since 2011, she has also been co-directing the regulatory T cell therapy program at UCSF.
This talk was given at the Gladstone-UCSF Institute of Genomic Immunology Symposium on November 3, 2021.

[@nfiniteplanets4869]

Hello Dr. Tang, I have a 22 year old daughter who received a liver transplant in 2013 and has done extremely well up until this year. Her alkaline phosphatase AST/ALT levels have been elevated for months, and unfortunately, she has been diagnosed with chronic rejection. I have been interested in Treg therapy for some time, and she would be interested in enrolling in clinical trials for Treg therapy to modulate the immune response.

[@XeNos3131]

Hello Dr Tank, I would appreciate your reply enormously.. I am kidney transplanted since 2008 and wish to ask you. Would stem cell therapy performed in my arthritic shoulders affect my transplanted kidney?

[@madmaxski]

Just Awesome

[@edthoreum7625]

8:30 liver